Küçük hücreli akciğer kanseri olan yaşlı hastalarda tedavi

Yaşlı küçük hücreli akciğer kanseri olan hastalar tedaviden gençlere benzer şekilde yarar görürler, ancak daha sık tedaviye bağlı yan etki tecrübe ederler. Genel durumu iyi olan yaşlı hastalarda standart tedaviler uygulanmalıdır. Uygun olmayan hastalar için tedaviler değiştirilebilir. Yaşlı hastaların tedavilerine karar verebilmek için klinik çalışmalara gerek vardır.

Treatment in elderly patients with small cell lung cancer

The elderly small cell lung cancer patients’ benefit from treatment is similar to younger patients, but experience more treatment-related adverse effects. These patients of good performance status must be treated as standart treatments. Therapy may be modified fort he unfavorable groups. Clinical trials for older patients are needed, for treatment decisions.

PDF

___

1. Malek KS, Sillian RA. Cancer in the older population. In: Chang AE, Ganz PA, Hayes DF, et al (eds). Oncology: An Evidence-Based Approach. New York: Springer, 2006: 1708-20.
2. Ruckdeschel JC, Schwartz AG, Bepler G, et al. Cancer of the Lung NSCLC and SCLC. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (eds). Clinical Oncology. Philadelphia: Elsevier Churchill Livingstone, 2004: 1649-743.
3. Murren JR, Turrisi AT, Pass HI. Small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer Principles and Practice of Oncology. Philadelphia: LippincottWilliams & Wilkins, 2005: 810-44.
4. Witta SE, Kelly K. Chemotherapy for small cell lung cancer. In: Pass HI, Carbone DP, Minna JD, Johnson DH, Turrisi III AT (eds). Lung Cancer Principles and Practice. Philadelphia: Lippincott-Williams & Wilkins, 2005: 657-73.
5. Safond MJ, Artal-Cortes A, Sirera R, et al. Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. Lung Cancer 2009; 63: 83-7.
6. Shepherd FA, Bezjak A. Treatment of small cell lung cancer in the elderly patient. In: Pass HI, Carbone DP, Minna JD, et al (eds). Lung Cancer Principles and Practice. Philadelphia: Lippincott-Williams & Wilkins, 2005: 692-703.
7. Mantovani C, Novello S, Ragona R, et al. Chemoradiotherapy in lung cancer: State of the art with focus on elderly population. Ann Oncol 2006; 17: 61-3.
8. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618-24.
9. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10: 890-5.
10. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 476-84.
11. Johnson BE, Bridges JD, Sobczeck M, et al. Patients with limited-stage small cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin and vincristine. J Clin Oncol 1996; 14: 806-13.
12. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol 2007; 25: 1898-907.
13. Quon H, Stepherd FA, Payne DG, et al. The influence of age on the delivery, tolerance and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 43: 39-45.
14. Feld R, Evans WK, Coy P, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations with limited stage small-cell lung cancer. J Clin Oncol 1987; 5: 1401-9.
15. Turrisi AT, Kim K, Blum R, et al. Twice daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265-71.
16. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000; 89: 1953-60.
17. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split course irradiation versus oncedaily irradiation for patients with limited stage small cell lung carcinoma. J Clin Oncol 1999; 17: 2681-91.
18. Schild SE, Bonner JA, Shanahan TG, et al. Long term results of a phase III trial comparing once daily radiotherapy or twice daily radiotherapy in limited-stage small cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59: 943-51.
19. Schild SE, Stella PJ, Brooks BJ, et al. Results of combined modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 2005; 103: 2349-54.
20. Pignon T, Gregor A, Schaake Koning C, et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 1998; 46: 239-48.
21. Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm or noncompliant patients with limitedstage small-cell lung cancer. J Clin Oncol 1998; 16: 3323-8.
22. Jeremic B, Shibamoto Y, Acimovic L, et al. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited stage small cell lung carcinoma: A phase II study. Cancer 1998; 82: 836-41.
23. Shepherd FA, Amdemichael E, Evans WK, et al. Treatment of small cell lung cancer in the elderly. J Am Geriatr 1994; 42: 64-70.
24. Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: A meta-analysis of controlled trials. Lancet 1993; 342: 1032-6.
25. Sekine I, Yamamoto N, Kunitoh H, et al. Treatment of small cell lung cancer in the elderly based on a critical review of clinical trials. Cancer Treat Rev 2004; 30: 359-68.
26. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol 2007; 25: 1898-907.